Biohaven BHVN -39.28% ▼ stock plummeted on Wednesday after the U.S. Food and Drug Administration (FDA) sent it a Complete Response Letter (CRL) for the clinical-stage biopharmaceutical company’s VYGLXIA New Drug Application (NDA). This NDA sought approval for VYGLXIA as a treatment for spinocerebellar ataxia (SCA), a group of inherited neurodegenerative disorders that affect the cerebellum and spinal cord, which leads to progressive loss of coordination and movement control.
https://www.tipranks.com/news/why-is-biohaven-stock-bhvn-down-40-today
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.